Investments in new processes and systems must satisfy the needs of the authorities and ensure patient safety and public confidence. Getting it right is likely to be expensive. but regulatory compliance shouldn’t be viewed purely as a cost center.
While companies developing solutions that address the current pandemic may be receiving an influx of financial support, recovery for companies in other segments of the industry is slow.
Having the ability to assess vital signs in real time could be the future of monitoring the health of travelers to help prevent outbreaks.
As COVID-19 sweeps the globe, it’s becoming increasingly difficult for medical device leaders to navigate the arising challenges and prepare for the future.
Networks enable the use of critical resources, including telehealth services, medical IoT technology,and staff and personal devices. It is critical to have a reliable WiFi network to support these devices.
One goal is to develop a fast, non-invasive way to evaluate skin rashes, such as ‘COVID toes’, for ischemia.
Simplifying the PMS process globally from end to end, can help medtech companies realize significant improvements across the board while keeping operating costs under control.
The pace of innovation in the ICU is orders of magnitude slower than that of the cath lab and OR, and the COVID-19 crisis has pushed, tested, and exposed ICUs for lacking state-of-the-art technology and resources.
Medtech companies will need to collaborate more closely with other parties in healthcare, as the aftermath of the coronavirus pandemic will have a comprehensive reach throughout the entire ecosystem. MTI speaks with Johnson & Johnson VP Raymond Fryrear, M.D. on the topic.
Illumina’s COVIDSeq Test enables qualitative detection of SARS-CoV-2 RNA from respiratory specimens.
